Fatty liver and psoriasis study pulled before it started
NCT ID NCT07255781
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to understand the link between non-alcoholic fatty liver disease (NAFLD) and psoriatic disease (psoriasis and psoriatic arthritis) in overweight adults. Researchers planned to use the drug guselkumab (Tremfya) to see if it improved both conditions. However, the trial was withdrawn before enrolling any participants, so no data or results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Guselkumab (Tremfya)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD - NONALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common blood thinner shield psoriasis Patients' arteries?
- Could a common b vitamin tame fatty liver?
- Can a new pill tame psoriasis? early safety trial begins
- Could a daily dose of citrus fiber tame fatty liver inflammation?
- Stick-On ultrasound patch could spot liver damage without a specialist
- Diet showdown: mediterranean vs DASH for fatty liver